Sermorelin: The First GHRH Analog
Sermorelin acetate is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of human growth hormone-releasing hormone (GHRH 1-29). It retains the full biological activity of the 44-amino-acid native GHRH and has been used extensively as a research tool for studying GH secretion physiology and the GHRH receptor system.
Receptor Pharmacology
Sermorelin activates the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, stimulating adenylyl cyclase activity and cAMP production through Gαs coupling. This leads to both acute GH secretion and longer-term effects on GH gene transcription and somatotroph proliferation in preclinical models.
Comparison with CJC-1295
While sermorelin and CJC-1295 both target the GHRH receptor, CJC-1295 incorporates amino acid substitutions that enhance metabolic stability and the DAC version adds albumin-binding capability. Sermorelin's shorter half-life more closely mimics the pulsatile pattern of endogenous GHRH, which some research protocols may prefer.
Research Applications
Sermorelin has been investigated in preclinical models for GH deficiency research, aging-related somatopause studies, body composition modulation, and as a diagnostic tool for pituitary GH reserve assessment. Its well-characterized pharmacology makes it a valuable reference compound in GH secretagogue research.
Research Disclaimer
This article is for educational and informational purposes only. All compounds discussed are intended strictly for in-vitro and preclinical research use. They are not intended for human consumption. Always consult published scientific literature and institutional review protocols before initiating any research program.